Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2013

Kandimalla Raju, Masius Roy, Beukers Willemien, Bangma Chris H, Orntoft Torben F, Dyrskjot Lars, van Leeuwen Nikki, Lingsma Hester, van Tilborg Angela A G, Zwarthoff Ellen C

Abstract excerpt

PURPOSE: DNA methylation is associated with bladder cancer and these modifications could serve as useful biomarkers. FGFR3 mutations are present in 60% to 70% of non-muscle invasive bladder cancer (NMIBC). Low-grade bladder cancer recurs in more than 50% of patients. The aim of this study is to determine the sensitivity and specificity of a urine assay for the diagnosis of recurrences in patients with a previous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CpG Islands

Share to DNA Methylation

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 23842048
DOI: 10.1158/1078-0432.CCR-12-3276

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.PMID 23842048Read ↗

A methylation assay for the detection of non‐muscle‐invasive bladder cancer (NMIBC) recurrences in voided urineSemantic proximity Read ↗

Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancerSemantic proximity Read ↗

A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.Semantic proximity Read ↗

Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.Semantic proximity Read ↗

A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysisSemantic proximity Read ↗

Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.Semantic proximity Read ↗

Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancerSemantic proximity Read ↗

Urine cell-based DNA methylation classifier for monitoring bladder cancerSemantic proximity Read ↗

A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC).Semantic proximity Read ↗

Methylation of a Novel Panel of Tumor Suppressor Genes in Urine Moves Forward Noninvasive Diagnosis and Prognosis of Bladder Cancer: A 2-Center Prospective StudySemantic proximity Read ↗

UroMark—a urinary biomarker assay for the detection of bladder cancerSemantic proximity Read ↗

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.